Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medicenna Therapeutics Corp (MDNA.TO)

Medicenna Therapeutics Corp (MDNA.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Medicenna Therapeutics Corp 2 Bloor Street West Suite 903 Toronto ON M4W 3E2 CAN

https://www.medicenna.com P: 416-964-5442

Sector:

Medical

Description:

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Key Statistics

Overview:

Market Capitalization, $K 77,573
Shares Outstanding, K 83,411
Annual Sales, $ 0 K
Annual Net Income, $ -11,805 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,883 K
60-Month Beta 3.37
% of Institutional Shareholders 0.43%

Growth:

1-Year Return -36.24%
3-Year Return 19.23%
5-Year Return -82.12%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.06 on 11/12/25
Next Earnings Date 02/12/25
Earnings Per Share ttm -0.17
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -54.05%
Dividend Payout Ratio 0.00%
Most Recent Split 1-14 on 03/03/17

MDNA.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -91.21%
Return-on-Assets % -54.21%
Profit Margin % 0.00%
Debt/Equity 0.01
Price/Sales N/A
Price/Book 7.57
Book Value/Share 0.12
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar